Stents CYPHER sirolimus-eluting

Polymers used in the CYPHER sirolimus-eluting stent... 

Polymers used in the CYPHER sirolimus-eluting stent. Abbreviations PBMA, poly-n-butyl methacrylate PEVA, polyethylene-co-vinyl acetate. 

Cordis Corporation. A Multi-Center, Non-Randomised Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Patient With an in-Stent Restenotic Native Coronary Artery Lesion (TROPICAL Study), 2006. 

DES in the United States at this time. They are the Cypher sirolimus-eluting stent manufactured by Cordis, a division of Johnson Johnson and the Taxus paclitaxel-eluting stent manufactured by Boston Scientific. 

The Cypher sirolimus-eluting stent from Cordis uses a blend of poly(ethylene-co-vinyl acetate) (PEVA) and poly(n-butyl methacrylate) (PBMA) as the polymeric matrix for sirolimus release. Both PEVA and PBMA have individually been used as implants in humans and demonstrated excellent biocompatibility. The blend of PEVA and PBMA is physically mixed with sirolimus in a weight ratio of 2 1. In vivo studies have shown that the majority of the drug is released in a sustained fashion in 30 days with complete drug release in 90 days as... 

In vivo sirolimus release profile from the Cypher sirolimus eluting stent. 

Ostojic, M., et al. First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-SIROLIMUS eluting stents NOBORI CORE nine months angiographic and one year clinical outcomes. Eurointervention 3, 574—579 (2008)... 

Cypher Instructions for Use. Cypher sirolimus-eluting coronary stent on Raptor over-the-wire delivery system, http // www.fda.gov/cdrh/PDF2/p020026c.pdf Accessed Aug 8, 2006. 

In long-term follow-up of the RAVEL trial (73), clinical benefit with sirolimus-eluting coronary stents has been maintained. Using cumulative one to three-year event-free survival rates, treatment with sirolimus-eluting stents was associated with a sustained clinical benefit and very low rates of target lesion revascularization up to three years after device implantation. As recently shown by both Kastrati and coworkers (74) and Windecker et al. (75), the Cypher stent eluting sirolimus is highly effective and may have clinical benefit beyond alternative DES products. 

Morice M-C, Serruys PVY, Colombo A, et al. Eight-month outcome of the REALITY Study a prospective, randomized, multi-center head-to-head comparison of the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus). Presented at the 2005 Annual Scientific Session ofthe American College of Cardiology, Orlando, FL, March 6-9, 2005. 

FDA (2003) Cypher Sirolimus-eluting coronary stent, summary of safety and effectiveness data. 

Urban, P., Gershlick, A. H., Guagliumi, G., et al. (2006) Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice One-Year Follow-Up of the e-Cypher Registry, Circulation, 113, 1434 1. 

With the recent development of angioplasty combined with DES such as the Cypher-Coronary Stent marketed by Cordis/J J Pharmaceuticals, treatment of the culprit vessel in myocardial infarction has had a significant and meaningful advance (69,70). By engineering the device to elute sirolimus... 

---